Anupam Rasayan India Limited – Credit Rating Update (NSE: ANURAS | BSE: 543275)

Introduction

On 31 August 2026, Anupam Rasayan India Limited (ARIL) filed an intimation with the BSE and NSE under Regulation 30 of the SEBI Listing Regulations, notifying that CRISIL Ratings Limited has continued its credit ratings on the company’s bank facilities and non‑convertible debentures, all of which remain on a “Watch Developing” watch.

---

Rating Summary

Instrument	Amount (₹ Cr)	Long‑Term Rating	Short‑Term Rating	Regulator
Total Bank Loan Facilities	1,620	A+ / Watch Developing	A1 / Watch Developing	RBI
Non‑Convertible Debentures	160	A+ / Watch Developing	–	MCA

All ratings continue on “Rating Watch with Developing Implications”.

The rating action reflects CRISIL’s assessment that the company’s credit profile remains stable but is subject to ongoing monitoring, primarily due to the pending acquisition of a 43.3 %–48.2 % equity stake in Bliss GVS Pharma Ltd.

---

Key Drivers Behind the Rating

Strengths

• Established market position in custom synthesis and specialty chemicals with a client base of 31 multinationals and 75 domestic customers.
• Diversified revenue streams – pharma and polymer segments contributed >30 % of FY 2026 revenue, reducing reliance on agro‑chemicals.
• Strategic acquisitions – recent acquisition of Tanfac Industries (hydrogen fluoride & potassium fluoride producer) secures critical raw‑material supply.
• Strong financial risk profile – Net‑worth of ₹ 3,334 Cr and a Total‑Outside‑Liabilities‑to‑Adjusted‑Net‑Worth (TOLANW) ratio of 0.78× (Mar‑31‑2026).
• Liquidity – Cash & cash equivalents of ₹ 378 Cr; expected net cash accrual of ₹ 280‑350 Cr in FY 2027 against modest debt service (₹ 40 Cr).

Weaknesses

• Working‑capital intensity – Gross current assets cycle of 504 days (down from 646 days a year earlier) due to high inventory and receivables, though improving.
• Margin pressure – Operating margin fell to 22.19 % in FY 2026 from 27.67 % in FY 2025, reflecting limited ability to pass on higher input costs.
• Exposure to forex and raw‑material price volatility – >50 % of revenue is export‑derived; 15‑20 % of inputs are imported.

---

Recent Financial Performance (FY 2026 vs FY 2025)

Metric	FY 2026	FY 2025
Operating Income	₹ 2,365.46 Cr	₹ 1,438.72 Cr
Profit After Tax (PAT)	₹ 222.20 Cr	₹ 159.85 Cr
PAT Margin	9.39 %	11.11 %
Adjusted Debt / Adjusted Net‑Worth	0.54×	0.45×
Interest Coverage	3.53×	3.55×

Revenue growth was driven by higher sales in agro‑chemical, pharma and polymer divisions. The decline in PAT margin stems from cost‑pass‑through constraints.

---

Acquisition of Bliss GVS Pharma – Impact on Rating

• Deal size: 43.3 %–48.2 % equity stake; funding expected via ₹ 300 Cr debt plus a global investment fund equity component.
• Status: Acquisition process ongoing; expected completion September 2026.
• Rating implication: CRISIL expects the rating to remain within one notch pending clarity on final funding and regulatory approvals. The watch will be lifted once the transaction is finalized and financing is confirmed.

---

Outlook & Rating Sensitivity

Upward Factors

• Further improvement in working‑capital management (GCAs < 250 days).
• Sustained revenue diversification and volume growth in specialty‑chemical, pharma, and polymer lines.
• Maintenance of operating margin above 25 % (if cost pressures ease).

Downward Factors

• Persistent decline in revenue or operating margin falling below 18 %.
• Large, debt‑funded capital expenditures or a resurgence of a lengthy working‑capital cycle (GCAs > 450 days) pushing gearing above 1.0×.

CRISIL will continue to monitor these variables and may adjust the rating accordingly.

---

Regulatory & Compliance Notes

• The rating is disclosed in compliance with SEBI Listing Regulations, Regulation 30.
• No directors of CRISIL are part of its rating committee; the Board of ARIL does not discuss ratings in its meetings.
• The rating covers instruments regulated by RBI (bank facilities) and MCA (non‑convertible debentures).

---

Conclusion for Investors

Anupam Rasayan India Limited’s credit ratings remain A+ (Long‑Term) / A1 (Short‑Term) with a “Watch Developing” qualifier. The company shows solid revenue growth and a diversified business model, but faces short‑term margin pressure and a high working‑capital cycle. The pending acquisition of Bliss GVS Pharma is the primary catalyst for the watch status; successful financing and closure could stabilize the rating, while any delays or additional debt could trigger a downgrade. Investors should watch the acquisition progress, working‑capital trends, and margin recovery in upcoming quarterly updates.